# Carvedilol in Preventing Heart Failure in Childhood Cancer Survivors

> **NCT02717507** · PHASE2 · COMPLETED · sponsor: **Children's Oncology Group** · enrollment: 196 (actual)

## Conditions studied

- Hematopoietic and Lymphoid Cell Neoplasm
- Malignant Solid Neoplasm

## Interventions

- **DRUG:** Carvedilol
- **OTHER:** Laboratory Biomarker Analysis
- **OTHER:** Pharmacogenomic Study
- **OTHER:** Pharmacological Study
- **OTHER:** Placebo Administration
- **OTHER:** Quality-of-Life Assessment
- **OTHER:** Questionnaire Administration

## Key facts

- **NCT ID:** NCT02717507
- **Lead sponsor:** Children's Oncology Group
- **Sponsor class:** NETWORK
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2016-04-04
- **Primary completion:** 2022-06-30
- **Final completion:** 2025-03-31
- **Target enrollment:** 196 (ACTUAL)
- **Last updated:** 2025-04-23

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02717507

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02717507, "Carvedilol in Preventing Heart Failure in Childhood Cancer Survivors". Retrieved via AI Analytics 2026-06-08 from https://api.ai-analytics.org/clinical/NCT02717507. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*